Acute renal failure after treatment with sunitinib in a patient with multiple myeloma

Nelson Leung, Nathan A. Saucier, Steven R. Zeldenrust, Heidi D. Gunderson, Lynn D. Cornell

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Sunitinib is a multiple tyrosine kinase receptors inhibitor that is approved for the treatment of advanced renal cell carcinoma. Amongst its targets are fetal liver tyrosine kinase receptor 3 (FLT 3) and vascular endothelial growth factor receptor (VEGFR). Renal toxicity has not been reported from the trials, but several patients have been reported to develop a pre-eclampsia-like syndrome. We report the first case of acute tubular necrosis in a patient with multiple myeloma following treatment with sunitinib.

Original languageEnglish (US)
Pages (from-to)292-294
Number of pages3
JournalNDT Plus
Volume2
Issue number4
DOIs
StatePublished - Aug 2009

Fingerprint

Receptor Protein-Tyrosine Kinases
Multiple Myeloma
Acute Kidney Injury
Vascular Endothelial Growth Factor Receptor-3
Pre-Eclampsia
Renal Cell Carcinoma
Necrosis
Kidney
Liver
Therapeutics
sunitinib

Keywords

  • acute renal failure
  • drug toxicity
  • sunitinib

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Leung, N., Saucier, N. A., Zeldenrust, S. R., Gunderson, H. D., & Cornell, L. D. (2009). Acute renal failure after treatment with sunitinib in a patient with multiple myeloma. NDT Plus, 2(4), 292-294. https://doi.org/10.1093/ndtplus/sfp037

Acute renal failure after treatment with sunitinib in a patient with multiple myeloma. / Leung, Nelson; Saucier, Nathan A.; Zeldenrust, Steven R.; Gunderson, Heidi D.; Cornell, Lynn D.

In: NDT Plus, Vol. 2, No. 4, 08.2009, p. 292-294.

Research output: Contribution to journalArticle

Leung, N, Saucier, NA, Zeldenrust, SR, Gunderson, HD & Cornell, LD 2009, 'Acute renal failure after treatment with sunitinib in a patient with multiple myeloma', NDT Plus, vol. 2, no. 4, pp. 292-294. https://doi.org/10.1093/ndtplus/sfp037
Leung N, Saucier NA, Zeldenrust SR, Gunderson HD, Cornell LD. Acute renal failure after treatment with sunitinib in a patient with multiple myeloma. NDT Plus. 2009 Aug;2(4):292-294. https://doi.org/10.1093/ndtplus/sfp037
Leung, Nelson ; Saucier, Nathan A. ; Zeldenrust, Steven R. ; Gunderson, Heidi D. ; Cornell, Lynn D. / Acute renal failure after treatment with sunitinib in a patient with multiple myeloma. In: NDT Plus. 2009 ; Vol. 2, No. 4. pp. 292-294.
@article{8c50fdeb1bb54fddbe58326674f12053,
title = "Acute renal failure after treatment with sunitinib in a patient with multiple myeloma",
abstract = "Sunitinib is a multiple tyrosine kinase receptors inhibitor that is approved for the treatment of advanced renal cell carcinoma. Amongst its targets are fetal liver tyrosine kinase receptor 3 (FLT 3) and vascular endothelial growth factor receptor (VEGFR). Renal toxicity has not been reported from the trials, but several patients have been reported to develop a pre-eclampsia-like syndrome. We report the first case of acute tubular necrosis in a patient with multiple myeloma following treatment with sunitinib.",
keywords = "acute renal failure, drug toxicity, sunitinib",
author = "Nelson Leung and Saucier, {Nathan A.} and Zeldenrust, {Steven R.} and Gunderson, {Heidi D.} and Cornell, {Lynn D.}",
year = "2009",
month = "8",
doi = "10.1093/ndtplus/sfp037",
language = "English (US)",
volume = "2",
pages = "292--294",
journal = "CKJ: Clinical Kidney Journal",
issn = "2048-8505",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Acute renal failure after treatment with sunitinib in a patient with multiple myeloma

AU - Leung, Nelson

AU - Saucier, Nathan A.

AU - Zeldenrust, Steven R.

AU - Gunderson, Heidi D.

AU - Cornell, Lynn D.

PY - 2009/8

Y1 - 2009/8

N2 - Sunitinib is a multiple tyrosine kinase receptors inhibitor that is approved for the treatment of advanced renal cell carcinoma. Amongst its targets are fetal liver tyrosine kinase receptor 3 (FLT 3) and vascular endothelial growth factor receptor (VEGFR). Renal toxicity has not been reported from the trials, but several patients have been reported to develop a pre-eclampsia-like syndrome. We report the first case of acute tubular necrosis in a patient with multiple myeloma following treatment with sunitinib.

AB - Sunitinib is a multiple tyrosine kinase receptors inhibitor that is approved for the treatment of advanced renal cell carcinoma. Amongst its targets are fetal liver tyrosine kinase receptor 3 (FLT 3) and vascular endothelial growth factor receptor (VEGFR). Renal toxicity has not been reported from the trials, but several patients have been reported to develop a pre-eclampsia-like syndrome. We report the first case of acute tubular necrosis in a patient with multiple myeloma following treatment with sunitinib.

KW - acute renal failure

KW - drug toxicity

KW - sunitinib

UR - http://www.scopus.com/inward/record.url?scp=77955973922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955973922&partnerID=8YFLogxK

U2 - 10.1093/ndtplus/sfp037

DO - 10.1093/ndtplus/sfp037

M3 - Article

AN - SCOPUS:77955973922

VL - 2

SP - 292

EP - 294

JO - CKJ: Clinical Kidney Journal

JF - CKJ: Clinical Kidney Journal

SN - 2048-8505

IS - 4

ER -